Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022.
adjuvant therapy child
adult
adult-onset recurrent respiratory papillomatosis juvenile-onset papillomatosis
recurrent respiratory papillomatosis
systemic bevacizumab
treatment
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
26 Dec 2022
26 Dec 2022
Historique:
received:
25
07
2022
revised:
05
12
2022
accepted:
14
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy.
OBJECTIVE
OBJECTIVE
This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment.
METHODS
METHODS
Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly.
RESULTS
RESULTS
Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them.
CONCLUSION
CONCLUSIONS
SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.
Identifiants
pubmed: 36670605
pii: children10010054
doi: 10.3390/children10010054
pmc: PMC9856545
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Laryngoscope Investig Otolaryngol. 2018 Jan 14;3(1):22-34
pubmed: 29492465
Pneumologie. 2009 Jul;63(7):387-9
pubmed: 19591084
Arch Argent Pediatr. 2019 Feb 1;117(1):e72-e76
pubmed: 30652461
N Engl J Med. 1988 Aug 18;319(7):401-7
pubmed: 3398891
Am J Case Rep. 2017 Jul 31;18:842-846
pubmed: 28757601
Laryngoscope. 2017 Jul;127(7):1538-1542
pubmed: 27996119
Am J Respir Crit Care Med. 2018 Feb 15;197(4):539-541
pubmed: 28968150
Int J Pediatr Otorhinolaryngol. 2020 Feb;129:109762
pubmed: 31707187
Ann Otol Rhinol Laryngol. 1993 Aug;102(8 Pt 1):580-3
pubmed: 8394667
Respir Med. 2017 May;126:116-121
pubmed: 28427542
Laryngoscope. 2008 Jan;118(1):50-5
pubmed: 17975511
Indian J Otolaryngol Head Neck Surg. 2021 Aug 18;:1-4
pubmed: 34426784
Laryngoscope. 2021 Jun;131(6):E1926-E1933
pubmed: 33382105
Am J Otolaryngol. 2021 Sep-Oct;42(5):103126
pubmed: 34175693
Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1039-42
pubmed: 15381589
Front Pharmacol. 2019 Apr 26;10:426
pubmed: 31105567
Int J Pediatr Otorhinolaryngol. 2020 Jan;128:109706
pubmed: 31610441
Laryngoscope. 2017 Oct;127(10):2225-2229
pubmed: 28657692
Laryngoscope. 2004 Nov;114(11 Pt 2 Suppl 104):1-23
pubmed: 15514560
J Immunother Cancer. 2019 May 3;7(1):119
pubmed: 31053174
Sex Transm Dis. 2014 May;41(5):300-5
pubmed: 24722383
MAbs. 2010 Mar-Apr;2(2):165-75
pubmed: 20190566
Anticancer Res. 2011 Nov;31(11):3953-7
pubmed: 22110225
Front Pediatr. 2019 Sep 18;7:383
pubmed: 31620412
Ear Nose Throat J. 2021 Aug 15;:1455613211040578
pubmed: 34392730
Oncol Lett. 2014 Nov;8(5):1912-1918
pubmed: 25289079
Laryngoscope. 2019 Apr;129(4):1001-1004
pubmed: 30588638
Ann Otol Rhinol Laryngol. 2014 Mar;123(3):214-21
pubmed: 24633948